PEP/NEWS — Peptide intel. Daily.

Use Code THOMAS for up to 31% off and $25 worth of free gifts from Manukora: http://manukora.com/thomas20 This video does contain a paid partnership with a brand that helps to support this channel. It is because of brands like this that we

Max Levchin is a serial entrepreneur and investor in 100+ startups. He's the founder and CEO of Affirm, the payment network powering consumer purchases and merchant growth. An original PayPal co-founder, Max served as CTO until its 2002 acq

In this video, Dr. Rena Malik explains what research actually says about penis size, including the true average length, why most men overestimate what’s normal, and whether length or girth really matters for sexual satisfaction. She also br

Peter Attia's AMA #86 digs into new data on GLP-1 receptor agonists — drugs like semaglutide — and lean mass loss during weight reduction. His take: patients who hit protein targets and do resistance training lose very little muscle. Context and protocol matter far more than the drug alone.

Lifespan.io's June 2026 roundup covers genomic-level aging interventions and new non-profit launches in the longevity space. A solid monthly digest for tracking where the field is moving.

A new study used aging trajectories of specific cell types — not whole-body clocks — to predict disease onset. Organ-level aging rate diverges sharply from chronological age, which has direct implications for peptide interventions targeting tissue-specific repair.

Researchers found a primate-specific non-coding RNA strand linked to cellular senescence — the buildup of damaged, non-dividing cells that drives aging. The discovery is relevant to any anti-aging strategy targeting the senescent cell burden, including peptide senolytic research.

This episode explores how RNA profiling and AI are making personalized metabolic health a reality. For peptide researchers, the microbiome-metabolism link discussed here is directly relevant to GLP-1 class compounds and metabolic peptide stack design.

Bryan Johnson details four cardiovascular protocols that he credits with giving him blood pressure and vascular function in the range of an 18-year-old. The stack relies on lifestyle and measurement — not peptides — but the biomarker framework maps directly onto longevity optimization work.

A new study links accelerated biological aging to rising rates of solid cancers in younger adults — and finds the trend is worsening with each generation. This is the backdrop against which peptide oncology research (including GH secretagogue risk profiles) must be evaluated.

NeuroAge Therapeutics is launching Younger 2027 — a six-month contest measuring biological age change on a clinical-grade panel. Baseline kits ship September 1, 2026. This kind of real-world N-of-many data on aging interventions is exactly what the peptide community needs more of.

A foundation-level breakdown of cancer biology for peptide researchers — covering the signaling pathways that tumors exploit and why understanding them matters before stacking GH-axis or angiogenic peptides.